ACADIA Pharmaceuticals Sees Record Sales, Raises 2025 Guidance
Acadia Pharmaceuticals Inc. (ACAD) delivered a strong third-quarter earnings report, showcasing robust growth across its key pharmaceutical products, NUPLAZID and DAYBUE, and demonstrating a solid financial position with $847 million in cash reserves. Total revenue for the quarter reached $278.6 million, a significant 11% increase compared to the prior year’s performance, driven primarily by record net sales for DAYBUE and continued strong performance of NUPLAZID. DAYBUE, the company’s flagship product for the treatment of insomnia, achieved its highest net sales figure to date at $101.1 million, fueled by prescriptions delivered to over 1,000 unique patients globally, representing a significant milestone for the company. NUPLAZID, used to treat psychosis associated with schizophrenia, also delivered record net sales of $177.5 million, reflecting a 12% year-over-year growth rate, bolstered by a 9% increase in patient volume.
Key Financial Highlights and Performance Metrics
The company’s strong financial health is underscored by its substantial cash balance. At the close of the third quarter, Acadia Pharmaceuticals held $847 million, a notable increase from $762 million reported in the second quarter, demonstrating considerable financial flexibility and capacity to invest in future growth initiatives. Research and Development (R&D) expenses for the quarter rose to $87.8 million, an increase from $66.6 million in the previous year, primarily due to higher clinical trial spending associated with advancing its pipeline programs. Selling, General and Administrative (SG&A) expenses remained flat at $133.4 million compared to the prior year, indicating careful management of operational costs. The board of directors subsequently raised its full-year 2025 guidance for NUPLAZID to a range of $685 million to $695 million, reflecting confidence in the product’s continued growth trajectory. The guidance for DAYBUE was also adjusted to $385 million to $400 million, while R&D expenses are projected to reach $335 million to $345 million for the full year. Furthermore, SG&A expense guidance has been set at $540 million to $555 million.
Pipeline Developments and Strategic Initiatives
Beyond the strong performance of its existing products, Acadia Pharmaceuticals is actively investing in its pipeline with promising developments. The company initiated a Phase 2 study for ACP-204, a novel treatment for Lewy Body Dementia Psychosis, and concurrently launched a Phase 3 study of trofinetide in Japan, demonstrating a continued commitment to expanding its therapeutic reach. The company’s strategic expansion includes significant investments in its field force, geared towards optimizing prescription pull-through and driving increased adoption of NUPLAZID. Thomas Garner, Chief Commercial Officer, explained that this expansion, planned for Q1 of next year, targets both community and long-term care (LTC) settings, anticipating growth across all channels. The company seeks to optimize prescription acquisition wherever new NUPLAZID scripts are generated.
Insights from Recent Earnings Call Q&A
Recent questions from analysts during the earnings call provided valuable insight into the company’s strategic outlook. Elizabeth Thompson, Executive Vice President and Head of Research and Development, clarified that SAPS HD, a clinically meaningful score used in the ACP-204 study, is a well-understood endpoint derived from previous trials, with the Phase 2 study powered for a moderate effect size of 0.4. The objective is to assess efficacy and ensure the drug’s appropriateness for Alzheimer’s patients, focusing on avoiding adverse effects like sedation and motor issues. Regarding DAYBUE, Thomas Garner noted that the product experienced its highest referral rate since launch, with continued growth expected into 2026. Elizabeth Thompson added that Phase 2 enrollment for ADP (Acute Dopaminergic Neuropsychiatric Disorder) is expected to complete around Q2, with top-line results anticipated mid-year, driven by a targeted approach to patient selection.
Outlook and Future Expectations
Analysts also probed the company’s expectations regarding peak sales projections. Catherine Owen Adams, CEO, revealed an updated peak sales aspiration of $11 billion, acknowledging a prior target of $2.5 billion to $12 billion, adjusted for the failure of the ACP-101 program. The commercial brands, NUPLAZID and DAYBUE, are projected to achieve $1.5 billion to $2 billion, with a greater degree of clarity anticipated to be revealed next year. Overall, Acadia Pharmaceuticals’ third-quarter results paint a positive picture, driven by robust product performance and strategic investments in its pipeline. The company’s strong financial position and promising pipeline developments suggest continued growth potential for years to come.
